Does anyone have any insight into this headline on the first page of the presentation?
Could it be that this organisation https://www.iqvia.com/solutions/real-world-evidence/health-economics-and-value has been engaged by PNV to facilitate the early completion of the current BARDA trial by presenting market-specific evidence? Something that both Swami and DW have alluded to in the recent past.
Perhaps we can expect an announcement in September this year to this effect? Or am I reading too much into it?
Ann: Macquarie Australia Conference - Presentation, page-23
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.42 |
Change
0.150(6.61%) |
Mkt cap ! $1.670B | |||
| Open | High | Low | Value | Volume |
| $2.33 | $2.42 | $2.29 | $4.630M | 1.958M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3536 | $2.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.43 | 38315 | 8 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| PNV (ASX) Chart |